Business
ADOCIA Reports Fourth Quarter 2025 Financial Results and Provides a Business Update
LYON, France, February 24, 2026--Regulatory News: Adocia (Euronext Paris: FR0011184241 – ADOC, the "Company"), a clinical-stage biopharmaceutical company focused on the research and development of innovative therapeutic solutions for the treatment of diabetes and obesity, reports financial results for the fourth quarter of 2025 and provides a business update.
About this update from Adocia Sa
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":3539,"height":1431,"url":"https://media.zenfs.com/en/business-wire.com/f4816509592b3db980f956b50cd07367"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/SPGZTsgJ4Xbt.ngl2vlONQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTM4ODtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/f4816509592b3db980f956b50cd07367","width":960,"height":388},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/20YrV4uPuGDGGyTEq4BLVQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTI0MDA7aD05NzA7Y2Y9d2VicA--/https://media.zenfs.com/en/business-wire.com/f4816509592b3db980f956b50cd07367","width":1200,"height":485}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"Chinese partner Tonghua Dongbao completed BioChaperone® Lispro Phase 3 program with positive data on people with type 1 diabetes, completing the positive results obtained on type 2 diabetes","length":189,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Continued development of BioChaperone® to stabilize and combine peptides for the treatment of obesity and diabetes, with two ongoing feasibility studies in collaboration with two large pharmaceutical companies","length":209,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Patent filed for a new technology platform AdoXLongTM that would allow once monthly peptide injections to treat obesity and diabetes, with initial positive in vitro and in vivo results generated with semaglutide","length":211,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Cash position of €17.2 million as of December 31, 2025, securing cash runway until beginning 2027, thanks to a €10 million fundraising completed in December 2025","length":161,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Gérard Soula to step down as Chairman of the Board of Directors, in accordance with the statutory age limit, Stéphane Boissel has been appointed Chairman of the Board, and Jacky Vonderscher has been co-opted as a Director","length":221,"tagName":"p","attribs":{}}]}],"tagName":"ul","bulletedList":true,"length":991,"olType":false},{"type":"text","content":"LYON, France, February 24, 2026--(BUSINESS WIRE)--Regulatory News:","length":71,"tagName":"p"},{"type":"text","content":"Adocia (Euronext Paris: ...